Eli Lilly and Company (LLY) Stock Analysis
A live, multi-source view of Eli Lilly and Company (LLY): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 50,000 employees · lilly.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Eli Lilly and Company (LLY) had a market capitalization of $1.02T, a trailing P/E of 38.6 (forward 24.3), a dividend yield of 0.60% and a beta of 0.50; the shares traded in a 52-week range of $712.05 – $1292.65 (57.0% over the year).
- Market cap
- $1.02T
- Enterprise value
- $1.07T
- Trailing P/E
- 38.6
- Forward P/E
- 24.3
- PEG ratio
- 1.12
- Price / book
- 30.24
- EPS (trailing)
- $29.80
- EPS (forward)
- $47.26
- Dividend yield
- 0.60%
- Payout ratio
- 21.7%
- Ex-dividend date
- 2026-08-14
- 52-week range
- $712.05 – $1292.65
- 52-week change
- 57.0%
- Beta
- 0.50
- Average volume
- 2.8M
- Shares outstanding
- 891.7M
- Short % of float
- 0.74%
- Profit margin
- 33.5%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Eli Lilly and Company (LLY) last closed at $1,123.00 (the last completed close before that scan).
Technicals at the scan: RSI 37 (neutral territory), price -5.5% versus its 20-day average, 20-day versus 50-day average spread +0.1%, MACD histogram -10.38.
Sentiment inputs: 71% of recent Finnhub-scored headlines read bullish; StockTwits 81% bullish; Reddit mentions 0% over 24 hours; analyst consensus score 72/100.
Next scheduled company event: in 48 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 2 buys and 6 sells of LLY; corporate insiders filed 0 buys and 3 sells (9 distinct filers, latest disclosure 2026-08-24). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Michael A. Rulli (1B/2S), John Boozman (0B/1S), Patrik Jonsson (0B/1S), Donald A. Zakrowski (0B/1S), Anat Hakim (0B/1S), Tommy Tuberville (0B/1S). Who is trading what
RapidTradeView pick record
LLY has been a daily pick 1 time; 1 of 1 graded picks beat SPY over the following five trading days. Most recent: 2026-08-06, rank #2, +0.22% versus SPY (beat). Full scoreboard
What this page covers
RapidTradeView pulls Eli Lilly and Company (LLY) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell LLY.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.